Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab)
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease. Please click here for an announcement from Bristol-Myers Squibb.
